Fate Therapeutics Inc, a four-year-old US company that is developing stem-cell modulators, has appointed William Rastetter as chairman and interim chief executive.
Dr Rastetter spent much of his career at IDEC Pharmaceuticals, acting as both chief executive and later as chairman. After the company’s merger with Biogen in 2003, he served as executive chairman of the combined group until the end of 2005. Subsequently, he became a co-founder of Receptos Inc., a drug discovery company, and a partner of Venrock Associates, a venture capital company
Copyright 2011 Evernow Publishing Ltd